March 28, 2020Open Access
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Key Result
Vericiguat reduced the incidence of cardiovascular death or heart failure hospitalization among high-risk patients compared to placebo.
Structured PICO
Does vericiguat reduce the incidence of death from cardiovascular causes or hospitalization for heart failure in patients with high-risk heart failure and reduced ejection fraction?
P
Population
Patients with high-risk heart failure and reduced ejection fraction
I
Intervention
Vericiguat
C
Comparator
Placebo
O
Outcome
Composite of death from cardiovascular causes or hospitalization for heart failurecomposite
Vericiguat reduces the composite of cardiovascular death or heart failure hospitalization in patients with high-risk heart failure and reduced ejection fraction compared to placebo.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo. (Funded by Merck Sharp VICTORIA ClinicalTrials.gov number, NCT02861534.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
P
Paul W. Armstrong
Heart Failure & Transplant
Burkert Pieske
Heart Failure & Transplant
K
Kevin J. Anstrom
Heart Failure & Transplant
Journals
New England Journal of Medicine
Actions
Institutions
Duke University
National University of Singapore
University of Alberta
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...